HSK3486
DrugHSK3486 for induction of general anesthesia.
NCT Number: NCT04711837
This is a multicenter, randomized, double-blinded, propofol-controlled, Phase 3 clinical study to evaluate the efficacy and safety of HSK3486 for induction of general anesthesia in adults undergoing elective surgery.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
Arizona Research Center, Phoenix, Arizona, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
HSK3486 for induction of general anesthesia.
Propofol for induction of general anesthesia.
Other names: Diprivan
Time frame: From start of drug administration to MOAA/S ≤1 (up to 5 minutes)
The primary outcome of interest was the success rate of anesthesia induction, defined by the proportion of subjects with successful anesthesia. A subject was considered successful for anesthetic induction if the following conditions were met: induction success Modified Observer's Assessment of Awareness/Sedation Scale (MOAA/S ≤1) after administration of study drug and 1 or less top-up dose required without using any rescue drugs. Where Grade 0 is no response after trapezius squeeze, Grade 1 responds only after painful trapezius squeeze and Grade 5 is completely awake responds to name spoken in normal tone.
Time frame: Up to 8 hours
Injection-site pain is evaluated verbally during study drug administration using the Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worse imaginable pain). Subjects' NRS pain score at the time of study drug administration (Day 1) and recall of pain score in PACU.
Time frame: 15 minutes from end of drug administration.
The proportion of subjects with successful induction who maintain the desired depth of anesthesia for general elective surgery, AND without significant cardiac and respiratory depression between the time of successful induction and 15 minutes post initiation of study drug administration, or up to the beginning of second tracheal intubation attempt if it is a difficult condition and not beyond 15 minutes post initiation of study drug administration.
Time frame: From start of drug administration to MOAA/S ≤1 (up to 5 minutes)
The proportion of subjects with any injection-site pain at time of drug administration on the Numeric Rating Scale (NRS ≥1).
Time frame: From end of drug administration to MOAA/S ≤1 (up to 5 minutes)
Time from the end of the first administration of the study drug to MOAA/S ≤1.
Time frame: From end of drug administration to disappearance of eyelash reflex (up to 5 minutes)
Time from the end of the first administration of the study drug to the disappearance of eyelash reflex.
Time frame: From start of drug administration to MOAA/S ≤1 (up to 5 minutes)
Failed to meet successful induction of general anesthesia defined by the use of the Top-up Study Drug and Rescue/Remediation Drugs
Haisco-USA Pharmaceuticals, Inc.
Industry
A Multicenter, Randomized, Double-blinded, Propofol-controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of HSK3486 Injectable Emulsion for Induction of General Anesthesia in Adults Undergoing Elective Surgery.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06993740
Anesthesia, Cardiovascular Diseases
Jakarta, DKI Jakarta, Indonesia
View Trial DetailsNCT07259629
Anesthesia, Glucose Metabolism Disorders
Exeter, Devon, United Kingdom
View Trial DetailsNCT03972423
Anesthesia, Anesthesia Complication
Versailles, IDF, France
View Trial DetailsNCT05111340
Aberrant Motor Behavior in Dementia, Anesthesia
Arras, France
View Trial Details